Efficacy of IL-6 receptor antagonist Mra in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA).

Efficacy of IL-6 receptor antagonist Mra in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA).

Bibliographic Details
Main Authors:	Maini, R, Taylor, P, Pavelka, K, Emery, P, Szechinski, J, Balint, G, Broll, J, Grp, C
Format:	Conference item
Published:	2003

Similar Items

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
by: Maini, R, et al.
Published: (2006)

Double-blind randomized controlled clinical-trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate (vol 54, pg 2817, 2006)
by: Maini, R, et al.
Published: (2008)

Infliximab and methotrexate in the treatment of rheumatoid arthritis
by: Lipsky, P, et al.
Published: (2000)

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2024)

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
by: Lipsky, P, et al.
Published: (2000)

The role of TNF alpha and IL-1 in rheumatoid arthritis.
by: Feldmann, M, et al.
Published: (2001)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
by: Taylor, P, et al.
Published: (2022)

Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
by: Taylor, P, et al.
Published: (2019)

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
by: Purcaru, O, et al.
Published: (2010)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
by: Keystone, E, et al.
Published: (2015)

INDIRECT TREATMENT COMPARISON TO COMPARE EFFICACY IN HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) SCORE FOR BIOLOGIC AGENTS WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ACTIVE DISEASE DESPITE METHOTREXATE THERAPY
by: Lebmeier, M, et al.
Published: (2010)

Methotrexate in psoriasis and psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
by: Maini, R, et al.
Published: (1998)

Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis.
by: Guyot, P, et al.
Published: (2011)

Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.
by: Guyot, P, et al.
Published: (2012)

The IL-20 cytokine family in rheumatoid arthritis and spondyloarthritis
by: Kragstrup, T, et al.
Published: (2018)

Rheumatoid arthritis.
by: Feldmann, M, et al.
Published: (1996)

Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
by: Taylor, P, et al.
Published: (2019)

Rheumatoid arthritis: introduction.
by: Feldmann, M, et al.
Published: (1998)

Immunotherapy for rheumatoid arthritis.
by: Taylor, P, et al.
Published: (2001)

Charisma and communities of feeling
by: Uzelac, Gordana
Published: (2020)

The 7 keys of charisma /
by: 389577 Kozubska, Joanna
Published: (1997)

Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis.
by: Andersson, A, et al.
Published: (2008)

Interleukin 10 (IL-10) haplotypes are associated with rheumatoid arthritis (RA).
by: MacKay, K, et al.
Published: (2000)

Cytokine therapy in rheumatoid arthritis.
by: Maini, R, et al.
Published: (1996)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
by: Taylor, P
Published: (2019)

Role of cytokines in rheumatoid arthritis.
by: Feldmann, M, et al.
Published: (1996)

Combination therapy with a TNF antagonist and a CD4 monoclonal antibody in rheumatoid arthritis. A pilot study.
by: Morgan, A, et al.
Published: (1997)

Distinction between charisma and vision.
by: Lim, Jacqueline Ai Hoon., et al.
Published: (2008)

The distinction between charisma and vision.
by: Lee, Tracy Hway.
Published: (2008)

Charisma, history and social structure/
by: Glassman, Ronald M., et al.
Published: (1986)

The role of IL-10 in rheumatoid arthritis (RA) in two ethnically diverse populations.
by: MacKay, K, et al.
Published: (1999)

The role of cytokines in the pathogenesis of rheumatoid arthritis.
by: Feldmann, M, et al.
Published: (1999)

Anti-cytokine therapy for rheumatoid arthritis.
by: Maini, R, et al.
Published: (2000)

Regulatory T-cell suppression is restored following methotrexate-mediated demethylation of the Foxp3 upstream enhancer in patients with rheumatoid arthritis
by: Cribbs, A, et al.
Published: (2014)

How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient?—MTX in the treat-to-target strategy
by: Taylor, P, et al.
Published: (2019)

TGF-β signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis
by: Peres, R, et al.
Published: (2018)

Cytokine expression in rheumatoid arthritis.
by: Brennan, F, et al.
Published: (1991)

Cytokine blockade in rheumatoid arthritis.
by: Feldmann, M, et al.
Published: (2001)

Rheumatoid arthritis
by: Taylor, P
Published: (2022)